To offer useful and efficient services, we need to know our customers well. For this reason, bioMérieux collects and processes data that are used in the interest of patients and to provide customers like you with quality services and support.
In a general context of data security and data privacy, bioMérieux is regularly consulted by its customers who want to be reassured or simply informed about the management of the data that are collected and processed through instruments and software, but also regarding the security of their bioMérieux systems.
This video features a cross interview with two experts: Patrick Lethenet, VP System Development Clinical Unit at bioMérieux and Christian Rivierre, VP systems & software engineering at Thales, our key partner in cybersecurity.
In addition to respecting demanding quality standards during the R&D and post-marketing phases, we integrate cybersecurity and data privacy measures early on in product design, conception, manufacture, testing and validation.
bioMérieux follows privacy and security standards such as HIPAA, HITECH, 21CFR part11 CLSI (AUTO11-A2), ISO, ANSSI and recent GDPR, as well as FDA, ANSM and CFDA clinical regulations and industrial integrity standards.
To learn more about GDPR at bioMérieux, click here.
Security & Control
- We ensure the protection and integrity of your data
The confidentiality and integrity of personal data are important, and we place cybersecurity at the heart of our business. Our teams of specialists constantly focus on ensuring optimal protection of your data.
- You retain control of your data
Our solutions are designed to so that you always retain control of your data. We are available to answer any questions you may have.
Microsoft has recently disclosed a critical vulnerability (CVE-2020-0601) affecting Windows capabilities to verify digital signatures which is a key feature for the validation of the authenticity of digital information. It can be exploited by a malicisous software, website or email to appear as signed by a trusted authority or by an attacker to decrypt confidential data in transit.
Several proofs of concept of the exploitation of this vulnerability have been publically disclosed soon after Microsoft's communication, but no exploitation have been reported at the time of the present publication.
Microsoft has released a set of patches as part of January's Windows Updates to correct this vulnerability. bioMérieux wants to inform its customers about this critical vulnerability and highly recommends any customer using systems running Windows 10 or Windows Server 2016 operating systems to install January's security updates according to each system's patch management procedure.
Ethics & Transparency
We collect and process technical data used by bioMérieux systems in a fair and transparent way.
The information we collect is used to provide you with the most relevant services and advice. It is entirely confidential and will never be sold to a third party.